Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

The Faculty of Medicine - Immunology and Cancer Research: Steinitz Michael

Researchers

Last updated December 2021 -  Immunology and Cancer Research

List of Publications

(1) Steinitz M. Preface. Methods Mol Biol 2019;1904:vii.

(2) Steinitz M. Human monoclonal antibodies in the clinic: Novel insights into the choice of specific targets. Hum Antibodies 2017;25(3-4):73-74.

(3) Steinitz M. Preface. Methods Mol Biol 2014;1060.

(4) Steinitz M. Production of human monoclonal antibodies by the epstein-barr virus method. Methods Mol Biol 2014;1060:111-122.

(5) Steinitz M. Erratum to: Human monoclonal antibodies [(2014), 1060, (E1), 10.1007/978-1-62703-586-6)]. Methods Mol Biol 2014;1060:E1.

(6) Laskov R, Yahud V, Hamo R, Steinitz M. Preferential targeting of somatic hypermutation to hotspot motifs and hypermutable sites and generation of mutational clusters in the IgVH alleles of a rheumatoid factor producing lymphoblastoid cell line. Mol Immunol 2011;48(5):733-745.

(7) Lindhagen-Persson M, Brännström K, Vestling M, Steinitz M, Olofsson A. Amyloid-Β oligomer specificity mediated by the IgM isotype - implications for a specific protective mechanism exerted by endogenous auto-antibodies. PLoS ONE 2010;5(11).

(8) Steinitz M. Immunotherapy for Alzheimer's disease. Immunother 2009;1(3):461-469.

(9) Steinitz M. Three decades of human monoclonal antibodies: Past, present and future developments. Hum Antibodies 2009;18(1-2):1-10.

(10) Chezar I, Lobel-Lavi L, Steinitz M, Laskov R. Ongoing somatic hypermutation of the rearranged VH but not of the V-lambda gene in EBV-transformed rheumatoid factor-producing lymphoblastoid cell line. Mol Immunol 2008;46(1):80-90.

(11) Perelberg A, Ilouze M, Kotler M, Steinitz M. Antibody response and resistance of Cyprinus carpio immunized with cyprinid herpes virus 3 (CyHV-3). Vaccine 2008;26(29-30):3750-3756.

(12) Steinitz M. Developing injectable immunoglobulins to treat cognitive impairment in Alzheimer's disease. Expert Opin Biol Ther 2008;8(5):633-642.

(13) Banks WA, Farr SA, Morley JE, Wolf KM, Geylis V, Steinitz M. Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: An age-related selective uptake with reversal of learning impairment. Exp Neurol 2007;206(2):248-256.

(14) Gil Y, Levy-Nabot S, Steinitz M, Laskov R. Somatic mutations and activation-induced cytidine deaminase (AID) expression in established rheumatoid factor-producing lymphoblastoid cell line. Mol Immunol 2007;44(4):494-505.

(15) Rosenmann H, Meiner Z, Geylis V, Abramsky O, Steinitz M. Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects. Neurosci Lett 2006;410(2):90-93.

(16) Geylis V, Steinitz M. Immunotherapy of Alzheimer's disease (AD): From murine models to anti-amyloid beta (Aβ) human monoclonal antibodies. Autoimmun Rev 2006;5(1):33-39.

(17) Geylis V, Kourilov V, Meiner Z, Nennesmo I, Bogdanovic N, Steinitz M. Human monoclonal antibodies against amyloid-beta from healthy adults. Neurobiol Aging 2005;26(5):597-606.

(18) Buchwald UK, Lees A, Steinitz M, Pirofski L-. A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice. Infect Immun 2005;73(1):325-333.

(19) Hutoran M, Britan E, Baraz L, Blumenzweig I, Steinitz M, Kotler M. Abrogation of Vif function by peptide derived from the N-terminal region of the human immunodeficiency virus type 1 (HIV-1) protease. Virology 2004;330(1):261-270.

(20) Pikarsky E, Ronen A, Abramowitz J, Levavi-Sivan B, Hutoran M, Shapira Y, et al. Pathogenesis of acute viral disease induced in fish by carp interstitial nephritis and gill necrosis virus. J Virol 2004;78(17):9544-9551.

(21) Mosolits S, Markovic K, Frödin J-, Virving L, Magnusson CGM, Steinitz M, et al. Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients. Clin Cancer Res 2004;10(16):5391-5402.

(22) Burns T, Zhong Z, Steinitz M, Pirofski L-. Modulation of Polymorphonuclear Cell Interleukin-8 Secretion by Human Monoclonal Antibodies to Type 8 Pneumococcal Capsular Polysaccharide. Infect Immun 2003;71(12):6775-6783.

(23) Ronen A, Perelberg A, Abramowitz J, Hutoran M, Tinman S, Bejerano I, et al. Efficient vaccine against the virus causing a lethal disease in cultured Cyprinus carpio. Vaccine 2003;21(32):4677-4684.

(24) Wines BD, Gavin A, Powell MS, Steinitz M, Buchanan RRC, Hogarth PM. Soluble FcγRIIa inhibits rheumatoid factor binding to immune complexes. Immunology 2003;109(2):246-254.

(25) Kourilov V, Steinitz M. Magnetic-bead enzyme-linked immunosorbent assay verifies adsorption of ligand and epitope accessibility. Anal Biochem 2002;311(2):166-170.

(26) Lechtzier V, Hutoran M, Levy T, Kotler M, Brenner T, Steinitz M. Sodium dodecyl sulphate-treated proteins as ligands in ELISA. J Immunol Methods 2002;270(1):19-26.

(27) Yu Y, Rabinowitz R, Steinitz M, Schlesinger M. Correlation between the expression of CD4 and the level of CD4 mRNA in human B-cell lines. Cell Immunol 2002;215(1):78-86.

(28) Mosolits S, Steinitz M, Harmenberg U, Ruden U, Eriksson E, Mellstedt H, et al. Immunogenic regions of the GA733-2 tumour-associated antigen recognised by autoantibodies of patients with colorectal carcinoma. Cancer Immunol Immunother 2002;51(4):209-218.

(29) Baraz L, Hutoran M, Blumenzweig I, Katzenellenbogen M, Friedler A, Gilon C, et al. Human immunodeficiency virus type 1 Vif binds the viral protease by interaction with its N-terminal region. J Gen Virol 2002;83(9):2225-2230.

(30) Blumenzweig I, Baraz L, Steinitz M, Kotler M, Friedler A, Gilon C, et al. HIV-1 Vif-derived peptide inhibits drug-resistant HIV proteases. Biochem Biophys Res Commun 2002;292(4):832-840.

(31) Steinitz M. Quantitation of the blocking effect of Tween 20 and bovine serum albumin in ELISA microwells. Anal Biochem 2000;282(2):232-238.

(32) Steinitz M, Baraz L. A rapid method for estimating the binding of ligands to ELISA microwells. J Immunol Methods 2000;238(1-2):143-150.

(33) Friedler A, Blumenzweig I, Baraz L, Steinitz M, Kotler M, Gilon C. Peptides derived from HIV-1 Vif: A non-substrate based novel type of HIV-1 protease inhibitors. J Mol Biol 1999;287(1):93-101.

(34) Lichtstein D, Levy T, Deutsch J, Steinitz M, Zigler Jr. JS, Russell P. The effects of digitalis-like compounds on rat lenses. Invest Ophthalmol Vis Sci 1999;40(2):407-413.

(35) Baraz L, Friedler A, Blumenzweig I, Nussinuv O, Chen N, Steinitz M, et al. Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production. FEBS Lett 1998;441(3):419-426.

(36) Lichtstein D, Steinitz M, Gati I, Samuelov S, Deutsch J, Orly J. Biosynthesis of digitalis-like compounds in rat adrenal cells: Hydroxycholesterol as possible precursor. Life Sci 1998;62(23):2109-2126.

(37) Lichtstein D, Steinitz M, Gati I, Samuelov S, Deutsch J, Orly J. Bufodienolides as Endogenous Na+, K+-ATPase Inhibitors: Biosynthesis in Bovine and Rat Adrenals. Clin Exp Hypertens 1998;20(42130):573-579.

(38) Siegall CB, Liggitt D, Chace D, Mixan B, Sugai J, Davidson T, et al. Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs. CLIN CANC RES 1997;3(3):339-345.

(39) Hanukoglu A, Omana J, Steinitz M, Rosler A, Hanukoglu I. Pseudohypoaldosteronism due to renal and multisystem resistance to mineralocorticoids respond differently to carbenoxolone. J Steroid Biochem Mol Biol 1997;60(1-2):105-112.

(40) Corper AL, Sohi MK, Bonagura VR, Steinitz M, Jefferis R, Feinstein A, et al. Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Nat Struct Biol 1997;4(5):374-381.

(41) Sohi MK, Corper AL, Wan T, Steinitz M, Jefferis R, Beale D, et al. Crystallization of a complex between the Fab fragment of a human immunoglobulin M (IgM) rheumatoid factor (RF-AN) and the Fc fragment of human IgG4. Immunology 1996;88(4):636-641.

(42) Steinitz M, Tamir S. An improved method to create nitrocellulose particles suitable for the immobilization of antigen and antibody. J Immunol Methods 1995;187(1):171-177.

(43) Fagerberg J, Steinitz M, Wigzell H, Askelöf P, Mellstedt H. Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci U S A 1995;92(11):4773-4777.

(44) Pascal V, Viktor K, Randen I, Thompson K, Steinitz M, Forre O, et al. Erratum: Analysis of Rheumatoid Factors and Polyreactive Antibodies derived from Patients with Rheumatoid Arthritis Reveals Diverse Use of V(H) and V(L) Gene segments and Extensive Variability in CDR-3 (Scandinavian Journal of Immunology (1992) 36, 349-362). Scand J Immunol 1994;40(1):125.

(45) Fagerberg J, Frödin J-, Ragnhammar P, Steinitz M, Wigzell H, Mellstedt H. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1) - II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy? Cancer Immunol Immunother 1994;38(3):149-159.

(46) Lubin I, Segall H, Marcus H, David M, Kulova L, Steinitz M, et al. Engraftment of human peripheral blood lymphocytes in normal strains of mice. Blood 1994;83(8):2368-2381.

(47) Steinitz M, Livoff A, Tamir S, Brenner T. Separation of rare cell subpopulations with the aid of biotin-labelled ligands. Med Oncol & Tumor Pharmacother 1993;10(1-2):49-52.

(48) Wirguin I, Steinitz M, Sicsic C, Abramsky O, Brenner T. Synthesis of antibodies against measles virus and myelin by in vitro stimulated B-cells derived from patients with subacute sclerosing panencephalitis. Immunol Lett 1993;38(1):55-58.

(49) FAGERBERG J, FRÖDIN J‐, RAGNHAMMAR P, STEINITZ M, WIGZELL H, MELLSTEDT H. Immunization Effect of Monoclonal Antibodies against Tumor‐Associated Antigens during Cancer Treatment. Ann New York Acad Sci 1993;690(1):337-339.

(50) Barrett DJ, Sleasman JW, Schatz DA, Steinitz M. Human anti-pneumococcal polysaccharide antibodies are secreted by the CD5- B cell lineage. Cell Immunol 1992;143(1):66-79.

(51) Steinitz M, Rosén A, Klein G. An improved dot immunobinding assay for screening hybridoma supernatants. Non-purified antigen immobilized on nitrocellulose paper discs. J Immunol Methods 1991;136(1):119-123.

(52) Frodin J-, Faxas M-, Hagstrom B, Lefvert A-, Masucci G, Nilsson B, et al. Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome - An important antitumoral effector function? Hybridoma 1991;10(4):421-431.

(53) Mellstedt H, Frodin J‐, Biberfeld P, Fagerberg J, Gisombe R, Hernandez A, et al. Patients treated with a monoclonal antibody (ab1) to the colorectal carcinoma antigen 17–1A develop a cellular response (DTH) to the “internal image of the antigen” (ab2). Int J Cancer 1991;48(3):344-349.

(54) Osterborg A, Steinitz M, Lewin N, Bergenbrant S, Holm G, Lefvert A-, et al. Establishment of idiotype bearing B-lymphocyte clones from a patient with monoclonal gammopathy. Blood 1991;78(10):2642-2649.

(55) Wirguin I, Brenner T, Steinitz M, Abramsky O. In vitro synthesis of antibodies to myelin antigens by Epstein-Barr virus-transformed B lymphocytes from patients with neurologic disorders. J Neurol Sci 1991;104(1):92-96.

(56) Engström P-, Norhagen E. G, Bottaro A, Carbonara AO, Lefranc G, Steinitz M, et al. Subclass distribution of antigen-specific IgA antibodies in normal donors and individuals with homozygous Cα1 or Cα2 gene deletions. J Immunol 1990;145(1):109-116.

(57) Steinitz M, Ingvarsson S, Asker C, Sümegi J, Klein G. Recombinant plasmid expressing the entire coding region of the Bmyc putative protein. J Clin Lab Immunol 1990;32(2):49-54.

(58) MALY F‐, URWYLER A, TENGLER R, STEINITZ M, GOLDING B, DE WECK AL. Oxidative Burst in Human Epstein‐Barr Virus‐Transformed B‐Cell Lines Triggered by Immobilized Specific Antigen. Scand J Immunol 1990;32(6):661-667.

(59) Minarovits J, Steinitz M, Boldog F, Imreh S, Wirschubsky Z, Ingvarsson S, et al. Differences in C‐myc and pvt‐1 amplification in sewa sarcoma sublines selected for adherent or non‐adherent growth. Int J Cancer 1990;45(3):514-520.

(60) Terness P, Berteli AJ, Steinitz M, Mytilineos J, Opelz G. IgM-anti-IgG antibody as cause of positive B-cell crossmatches. Transplant Proc 1990;22(4):1885-1886.

(61) Asker C, Steinitz M, Andersson K, Sumegi J, Klein G, Ingvarsson S. Nucleotide sequence of the rat Bmyc gene. Oncogene 1989;4(12):1523-1527.

(62) Mellstedt H, Frödin J-, Lindemalm C, Masucci G, Merk K, Pettersson D, et al. Biologic response modifiers in the treatment of gastrointestinal malignancies. Scand J Gastroenterol 1989;24(3):257-268.

(63) Brenner T, Timore Y, Wirguin I, Abramsky O, Steinitz M. In vitro synthesis of antibodies to acetylcholine receptor by Epstein-Barr virus-stimulated B-lymphocytes derived from patients with myasthenia gravis. J Neuroimmunol 1989;24(3):217-222.

(64) Steinitz M. B Cell clones in rheumatoid arthritis. Springer Semin Immunopathol 1988;10(2-3):181-188.

(65) Steinitz M, Tamir S, Sela SB, Rosenmann E. The presence of non-isotype-specific antibodies in polyclonal anti-IgE reagents: Demonstration of their binding to specifically selected Epstein-Barr virus-transformed cell lines. Cell Immunol 1988;113(1):10-19.

(66) Natvig JB, Førre Ø, Randen I, Steinitz M, Thompson K, Waalen K. B lymphocytes, b cell Clones and rheumatoid factor antibodies in rheumatoid inflammation. Scand J Rheumatol 1988;17(S76):217-227.

(67) Natvig JB, Thompson K, Randen I, Steinitz M, Taussig M, Beale D, et al. Partial amino acid sequence analysis and variable subgroup determination (VH and VL) of a monoclonal rheumatoid factor derived from a rheumatoid arthritis patient. Scand J Rheumatol 1988;17(S75):127-132.

(68) Steinitz M, Tamir S, Frodin J-, Lefvert A-, Mellstedt H. Human monoclonal anti-idiotypic antibodies. I. Establishment of immortalized cell lines from a tumor patient treated with mouse monoclonal antibodies. J Immunol 1988;141(10):3516-3522.

(69) Welsh CJR, Steinitz M, Clark MR, Coombs RRA. The detection of heat-aggregated IgG (as a model for immune complexes) by reverse passive haemagglutination using a human monoclonal rheumatoid factor coupled to erythrocytes. J Immunol Methods 1987;104(1-2):271-274.

(70) Schröder AK, Gharavi AE, Steinitz M, Johansson PJH, Christensen P. Binding of monoclonal IgM rheumatoid factor to streptococci via the antibody combining site. Int Arch Allergy Immunol 1987;83(1):88-91.

(71) Steinitz M, Tamir S, Ferne M, Goldfarb A. A protective human monoclonal IgA antibody produced in vitro: Anti‐pneumococcal antibody engendered by Epstein‐Barr virus‐immortalized cell line. Eur J Immunol 1986;16(2):187-193.

(72) Steinitz M, Tamir S. Solubilization of cell-membrane-antigen and its coupling to fixed and non-fixed erythrocytes. J Clin Lab Immunol 1985;18(4):195-198.

(73) Ebstein RP, Steinitz M, Mintzer J, Lipshitz I, Stessman J. Beta-adrenergic-stimulated adenylate cyclase activity in normal and EBV-transformed lymphocytes. Experientia 1985;41(12):1552-1554.

(74) Steinitz M, Tamir S. Human monoclonal antibodies produced by Epstein-Barr virus transformed cell lines bind protein A. Immunol Lett 1985;9(1):19-22.

(75) Steinitz M, Tamir S. The coating of erythrocytes with detergent-solubilized molecules: a general method for improved coupling of antigens and antibodies. J Immunol Methods 1985;76(1):27-38.

(76) Avital A, Tamir S, Steinitz M. Continuous in vitro production of IgA by a human colostral immortalized cell line. Immunol Lett 1985;9(1):23-27.

(77) Avital A, Steinitz M. Production of human monoclonal antibodies by Epstein-Barr virus-transformed cell lines. Harefuah 1984;107(7-8):167-168+220.

(78) Steinitz M, Tamir S, Goldfarb A. Human anti-pneumococci antibody produced by an Epstein Barr virus (EBV)-immortalized cell line. J Immunol 1984;132(2):877-882.

(79) Jefferis R, Nik Jaafar MI, Steinitz M. Immunogenic and antigenic epitopes of immunoglobulins. VIII. A human monoclonal rheumatoid factor having specificity for a discontinuous epitope determined by histidine/arginine interchange as residue 435 of immunoglobulin G. Immunol Lett 1984;7(4):191-194.

(80) Avital A, Tamir S, Faran M, Steinitz M. A sensitive assay to evaluate antistreptococcal antibodies using an in vitro-produced monoclonal human rheumatoid factor. Diagn Immunol 1983;1(2):75-79.

(81) Gamliel H, Steinitz M, Neeman Z, Polliack A. SCANNING IMMUNO-ELECTRON MICROSCOPY OF A MONOCLONAL, EPSTEIN-BARR VIRUS(EBV) TRANSFORMED HUMAN CELL LINE PRODUCING RHEUMATOID FACTOR IN-VITRO. Scanning Electron Microsc 1983;v(pt 1):271-278.

(82) Spira G, Steinitz M, Klein G. Low-molecular-weight (61K) mu chain in P3HR-1 cells and various derived somatic hybrids. Cell Immunol 1983;76(2):322-331.

(83) Steinitz M, Tamir S, Spira G, Siegert W. A sensitive method for detecting cells coated with antibodies with human monoclonal rheumatoid factor produced in vitro. J Immunol Methods 1982;54(3):273-280.

(84) Steinitz M, Koide N, Spira G, Tamir S, Klein G. In vitro produced monoclonal rheumatoid factor: Purification, radiolabel, and possible applications. Cell Immunol 1982;69(2):205-214.

(85) Steinitz M. Monoclonal antibodies from human cell lines. Z Anal Chem 1982;311(4):348-349.

(86) Steinitz M, Tamir S. In vitro production of human monoclonal antibodies by Epstein Barr Virus (EBV) cell lines: Practical applications of a monoclonal rheumatoid factor. Z Anal Chem 1982;311(4):360.

(87) Polke C, Greger B, Steinitz M, Eichmann K. Clonal Analysis of a Human Lymphoblastoid Cell Line (B17) Secreting Antibody to N-Acetyl-D-Glucosamine. Immunobiology 1982;163(1):95-109.

(88) Steinitz M, Tamir S. Human monoclonal autoimmune antibody produced in Vitro: rheumatoid factor generated by Epstein‐Barr virus‐transformed cell line. Eur J Immunol 1982;12(2):126-133.

(89) Steinitz M, Klein E. Human monoclonal antibodies produced by immortalization with Epstein-Barr virus. Immunol Today 1981;2(2):38-39.

(90) Steinitz M, Izak G, Cohen S, Ehrenfeld M, Flechner I. Continuous production of monoclonal rheumatoid factor by EBV-transformed lymphocytes. Nature 1980;287(5781):443-445.

(91) Steinitz M. Determination of immunoglobulin classes of specific antibodies secreted by single cells. A cluster formation assay. J Immunol Methods 1980;38(1-2):95-102.

(92) Steinitz M, Klein G. EBV-transformation of surface IgA-positive human lymphocytes. J Immunol 1980;125(1):194-196.

(93) Steinitz M, Koskimies S, Klein G, Makela O. Establishment of specific antibody producing human lines by antigen preselection and Epstein-Barr virus (EBV)-transformation. J Clin Lab Immunol 1979;2(1):1-7.

(94) Steinitz M, Seppala I, Eichmann K, Klein G. Establishment of a human lymphoblastoid cell line with specific antibody production against group A streptococcal carbohydrate. Immunobiology 1979;156(1-2):41-47.

(95) Steinitz M, Klein G. Superinfection of EBV-carrying lines with Herpes virus papio (HVP): Induction of early antigen (EA) and inhibition of cellular DNA synthesis. European Journal of Cancer (1965) 1979;15(2):217-222.

(96) Klein G, Manneborg A, Steinitz M. Differences in EBV receptor concentration between in vitro EBV‐converted lymphoma sublines reflect biological differences between the converting viral substrains. Int J Cancer 1979;23(2):197-200.

(97) KOZBOR D, STEINITZ M, KLEIN G, KOSKIMIES S, MÃKELÄ O. Establishment of Anti‐TNP Antibody‐producing Human Lymphoid Lines by Preselection for Hapten Binding followed by EBV Transformation. Scand J Immunol 1979;10(3):187-194.

(98) Bakacs T, Klein E, Steinitz M, Gergeley P. Surface markers and functional characteristics of human blood lymphocytes residing in the operational 'null' subset. Haematologia 1978;12(1-4):113-126.

(99) Steinitz M, Bakács T, Yefenof E, Klein G. Inhibition of dna metabolism in human b lymphocytes by a substrain of epstein-barr virus (P3hr-1): A method for virus quantitation. Intervirology 1978;10(2):125-131.

(100) Kiessling R, Fenyö EM, Steinitz M, Klein G, Haller O. Mouse natural killer (NK) cell activity against human cell lines is not influenced by superinfection of the target cell with xenotropic murine c‐type virus. Int J Cancer 1978;21(4):460-465.

(101) Steinitz M, Bakács T, Klein G. Interaction of the B95‐8 and P3HR‐1 substrains of epstein‐barr virus (EBV) with peripheral human lymphocytes. Int J Cancer 1978;22(3):251-257.

(102) Viallat J, Svedmyr E, Steinitz M, Klein G. Stimulation of peripheral human lymphocytes by autologous EBV genome-carrying lymphoblastoid cell lines. Cell Immunol 1978;38(1):68-75.

(103) Bakacs T, Klein E, Yefenof E, Gergely P, Steinitz M. Human blood lymphocyte fractionation with special attention to their cytotoxic potential. Z IMMUNITATSFORSCH 1978;154(2):121-134.

(104) Einhorn L, Steinitz M, Yefenof E, Ernberg I, Bakacs T, Klein G. Epstein-Barr virus (EBV) receptors, complement receptors, and EBV infectibility of different lymphocyte fractions of human peripheral blood. II. Epstein-Barr virus studies. Cell Immunol 1978;35(1):43-58.

(105) Steinitz M, Koskimies S, Klein G, Mäkelä O. Establishment of specific antibody producing human lines by antigen preselection and EBV-transformation. Curr Top Microbiol Immunol 1978;81:156-163.

(106) Steinitz M, Klein G, Koskimies S, Makel O. EB virus-induced B lymphocyte cell lines producing specific antibody. Nature 1977;269(5627):420-422.

(107) Gergely P, Ernberg I, Steinitz M. Blastogenic response of purified human T-lymphocyte populations to Epstein-Barr virus (EBV). Clin Exp Immunol 1977;30(3):347-353.

(108) Steinitz M, Klein G. Further studies on the differences in serum dependence in EBV negative lymphoma lines and their in vitro EBV converted, virus-genome carrying sublines. European Journal of Cancer (1965) 1977;13(11):1269-1275.

(109) Klein E, Neumann H, Steinitz M, Yefenof E. Epstein Barr Virus (EBV) determined characteristics in lymphoid cells. Bibl Haematol 1976;No.43:13-18.

(110) Steinitz M, Klein G. Epstein-Barr virus (EBV)-induced change in the saturation sensitivity and serum dependence of established, EBV-negative lymphoma lines in vitro. Virology 1976;70(2):570-573.

(111) Steinitz M, Klein G. Comparison between growth characteristics of an Epstein Barr virus (EBV) genome negative lymphoma line and its EBV converted subline in vitro. Proc Natl Acad Sci U S A 1975;72(9):3518-3520.

(112) Steinitz M, Feigis M, Weiss DW. Studies on the physiological manifestations of cell mediated cytotoxicity. II. Inhibition of [3H]thymidine incorporation by plasmacytoma cells exposed in vitro to sensitized splenocytes. Cell Immunol 1975;17(1):181-191.

(113) Steinitz M, Weiss DW. Studies on the physiological manifestations of cell-mediated cytotoxicity. I. Early metabolic changes in mouse plasmacytoma cells exposed in vitro to sensitized allogeneic splenocytes. Cell Immunol 1975;15(2):403-418.